The proportion of patients with more than 90% BTKOCC,7 as a function of ibrutinib total daily dose in the CLL population using three different types of BTK turnover: a fast turnover (BTK half-life of 24 h [17] with between-subject variability of 25%), a slow turnover (BTK half-life of 60 h [19] with between-subject variability of 25%) and a uniform distribution of BTK turnovers (half-lives ranging from 12 h to 120 h) is shown in Fig. 4. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.